Trials / Recruiting
RecruitingNCT06177821
Rezum for 30-80ml Patients With Moderate-severe LUTS to Study Surgical Principles for Median Lobe Enlargement
Feasibility of Water Vaporization (Rezum®) for Patients With ≥ 30 and < 80 ml With Moderate-severe LUTS to Establish the Surgical Principles for Prominent or Non-prominent Median Lobe Enlargement: A Single-center, Prospective, Pilot Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- Male
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study was created to determine the safety and efficacy of treating prostatic hyperplasia with or without prominent median lobe enlargement with the REZUM technique. The systematic implementation of decisions for the location, vapor time, and the number of injections contributes to the Rezum procedure configuration for the median lobe treatment being safer and standardizer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Rezum® | Rezum® Water vaporization device |
Timeline
- Start date
- 2024-06-03
- Primary completion
- 2024-06-17
- Completion
- 2025-12-30
- First posted
- 2023-12-20
- Last updated
- 2024-04-19
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06177821. Inclusion in this directory is not an endorsement.